Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2025-05-29 Share Issue/Capital Cha…
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
Cleansing Notice 1 page 194.8KB
Share Issue/Capital Change Classification · 100% confidence The document is a cleansing notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) related to the issue of new shares by 4DMedical Limited. It references the issuance of shares as earnout consideration for an acquisition and compliance with disclosure requirements. The document is short (2127 characters) and is a formal notice to the ASX regarding share issuance and compliance, not a full financial report or detailed filing. It does not contain financial statements or detailed analysis, nor is it a report publication announcement. This fits the category of Share Issue/Capital Change announcements, which cover new share issues and related notices.
2025-05-29 English
Application for quotation of securities - 4DX 7 pages 20.2KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the number and type of securities to be quoted, references previous announcements (Appendix 3B), and provides information about the issuance of securities as earnout consideration related to an acquisition. There are no financial statements or detailed financial performance data, nor is this a report or announcement of voting results or management changes. The document is a formal regulatory filing related to capital market activities but does not announce new financing or capital structure changes directly; rather, it applies for quotation of securities already issued or to be issued as part of a previously announced transaction. This fits the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like Capital/Financing Update or Share Issue/Capital Change, since it is specifically an application for quotation rather than the issuance announcement itself.
2025-05-28 English
Investor Presentation - FDA Submission for CTVQ 34 pages 3.5MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation prepared by 4DMedical Limited dated 27 May 2025. It contains extensive information about the company's product portfolio, regulatory clearances, clinical evaluation studies, and comparative analyses of their lung imaging technology CT:VQ versus existing nuclear imaging methods. The content is structured as a presentation with slides, including disclaimers, product descriptions, clinical study results, and market opportunity discussions. There is no indication that this is an official annual or interim financial report, audit report, or regulatory filing. It is not a transcript of a call, nor a voting result or management change announcement. The document is clearly intended for investors or stakeholders to inform them about the company's technology, clinical validation, and market potential. This matches the definition of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2025-05-26 English
4DMedical files FDA submission for CTVQ 7 pages 785.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 26 May 2025 from 4DMedical Limited regarding the filing of an FDA 510(k) submission for a new medical device software product called CT:VQ™. The text details the product, its clinical validation, regulatory pathway, and commercial opportunity. It is a regulatory announcement about a submission to the FDA, not a financial report, earnings release, or management discussion. The document is lengthy (15,000 characters) and contains detailed information about the submission and product but does not contain financial statements or earnings data. It is not a report publication announcement since it is the announcement itself, not a notice of report availability. The content fits best under Capital/Financing Update (CAP) as it relates to a significant regulatory filing impacting the company's product commercialization and potential revenue streams. Therefore, the filing type is CAP with high confidence.
2025-05-25 English
4DMedical wins commercial contract with Intermountain Health 2 pages 208.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 5 May 2025, describing a commercial contract win by 4DMedical with Intermountain Health. It details the nature of the contract, the product involved, and the strategic partnership with Nuance Communications. The content is a business update about a contract win and future revenue potential, without any financial statements, earnings data, or regulatory filings. It is not a report, earnings release, or regulatory filing but a capital/financing update related to commercial contracts and business development. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-05-04 English
Application for quotation of securities - 4DX 7 pages 23.4KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the issuance and quotation of new securities (options) including their terms, issue date, and distribution. It references related prospectuses and previous announcements but does not contain financial statements or performance data. The document is regulatory in nature, focused on capital market compliance and listing requirements rather than reporting financial results or management commentary. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2025-05-01 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.